Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
GMPR2 Antibody
NCTP07458
Description: Rabbit polyclonal to human GMPR2
Application: ELISA, WB, IHC
Reactivity: Human
Catalog #: NCTP07458
Application: ELISA, WB, IHC
Reactivity: Human
Catalog #: NCTP07458
$380.00
1000 Items
Overview
| DESCRIPTION | |
| Species Reactivity | Human. Predicted reacts with rat, mouse. Other species not tested. |
| Isotype | IgG |
| Immunogen | Recombinant human GMPR2 protein 17-182aa |
| Accession # | Q9P2T1 |
| Alternative Names | GMP reductase 2, Guanosine monophosphate reductase 2 |
| Purification | Purified by protein affinity column. |
| Formulation | Lyophilized with 1% BSA and 0.02% NaN3. |
| Size | 100µg/200µl |
| APPLICATION | |
| ELISA | 1:20,000-1:80,000 |
| Western Blot | 1:200-1:1,000 |
| Immunohistochemistry | 1:100-1:500 |
| - | For research use only. Optimal dilutions/concentrations should be determined by each laboratory for each application. |
| PREPARATION AND STORAGE | |
| Reconstitution | Reconstitute in 200µl of sterile H2O. |
| Storage | Shipped at ambient temperature. Store immediately at -20°C upon receipt. Avoid repeated freeze-thaw cycles. |
| REFERENCES | |
| - | Baker, B.G., Ball, G.R., Rakha, E.A., et al. Lack of expression of the proteins GMPR2 and PPARalpha are associated with the basal phenotype and patient outcome in breast cancer. Breast Cancer Res. Treat. 137 (1), 127-137 (2013). |